Yakun Wang1, Aihong Yuan, Chen Yu. 1. Department of Nephrology, Tongji Hospital of Tongji University Shanghai, 200065.
Abstract
OBJECTIVE: This study aimed to investigate the relationship between microalbuminuria (MAU) and cardiovascular events. METHODS: A total of 1259 hospitalized patients who received urinary albumin detection were recruited from Tongji Hospital of Tongji University in 2012. They were divided into two groups according to the level of urinary albumin: normal albuminuria (NAU) group (n=907) and MAU group (n=352). General information and cardiovascular events were collected and further analyzed. RESULTS: Patients in MAU group was elder than those in NAU group (P<0.01), and the prevalence of diabetes and/or hypertension in MAU group was significantly higher than that in NAU group (P<0.01). The prevalence of major cardiovascular events (unstable angina, non-ST-segment elevation myocardial infarction and ST-segment elevation myocardial infarction) and congestive heart failure requiring therapy in hospital in MAU group was significantly higher than that in NAU group (P<0.01). Logistic regression analysis showed patients in MAU group had higher risk for major cardiovascular events (OR 1.438, 95% CI 1.018-2.031) and congestive heart failure (OR 2.540, 95% CI 1.717 to 3.757). CONCLUSIONS: MAU increases the risk for major cardiovascular events and congestive heart failure. MAU is an independent risk factor of cardiovascular events. Patients with MAU (30-300 mg/24 h) should be treated timely to reduce the incidence of cardiovascular events and delay the progression of cardiovascular diseases, which is independent of presence of diabetes and/or hypertension.
OBJECTIVE: This study aimed to investigate the relationship between microalbuminuria (MAU) and cardiovascular events. METHODS: A total of 1259 hospitalized patients who received urinary albumin detection were recruited from Tongji Hospital of Tongji University in 2012. They were divided into two groups according to the level of urinary albumin: normal albuminuria (NAU) group (n=907) and MAU group (n=352). General information and cardiovascular events were collected and further analyzed. RESULTS:Patients in MAU group was elder than those in NAU group (P<0.01), and the prevalence of diabetes and/or hypertension in MAU group was significantly higher than that in NAU group (P<0.01). The prevalence of major cardiovascular events (unstable angina, non-ST-segment elevation myocardial infarction and ST-segment elevation myocardial infarction) and congestive heart failure requiring therapy in hospital in MAU group was significantly higher than that in NAU group (P<0.01). Logistic regression analysis showed patients in MAU group had higher risk for major cardiovascular events (OR 1.438, 95% CI 1.018-2.031) and congestive heart failure (OR 2.540, 95% CI 1.717 to 3.757). CONCLUSIONS:MAU increases the risk for major cardiovascular events and congestive heart failure. MAU is an independent risk factor of cardiovascular events. Patients with MAU (30-300 mg/24 h) should be treated timely to reduce the incidence of cardiovascular events and delay the progression of cardiovascular diseases, which is independent of presence of diabetes and/or hypertension.
Authors: A Y T Wu; N C T Kong; F A de Leon; C Y Pan; T Y Tai; V T F Yeung; S J Yoo; A Rouillon; M R Weir Journal: Diabetologia Date: 2004-12-23 Impact factor: 10.122
Authors: H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf Journal: JAMA Date: 2001-07-25 Impact factor: 56.272
Authors: Janine Pöss; Christian Ukena; Felix Mahfoud; Christoph Gensch; Christian Werner; Martin Thoenes; Peter Bramlage; Massimo Volpe; Ulrich Laufs; Michael Böhm Journal: Eur J Prev Cardiol Date: 2011-09-07 Impact factor: 7.804
Authors: H L Hillege; W M Janssen; A A Bak; G F Diercks; D E Grobbee; H J Crijns; W H Van Gilst; D De Zeeuw; P E De Jong Journal: J Intern Med Date: 2001-06 Impact factor: 8.989
Authors: Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn Journal: Lancet Date: 2002-03-23 Impact factor: 79.321
Authors: Marek Vecka; Magdalena Dušejovská; Barbora Stankova; Miroslav Zeman; Lucie Vavrova; Jana Kodydkova; Adolf Slaby; Ales Zak Journal: Neuro Endocrinol Lett Date: 2012 Impact factor: 0.765
Authors: Emin Murat Akbas; Aysu Timuroglu; Adalet Ozcicek; Fatih Ozcicek; Levent Demirtas; Adem Gungor; Nergis Akbas Journal: Int J Clin Exp Med Date: 2014-12-15
Authors: Emin Murat Akbas; Levent Demirtas; Adalet Ozcicek; Aysu Timuroglu; Eftal Murat Bakirci; Hikmet Hamur; Fatih Ozcicek; Kultigin Turkmen Journal: Int J Clin Exp Med Date: 2014-07-15
Authors: Edna N Matjuda; Godwill A Engwa; Prescilla B Letswalo; Muhau M Mungamba; Constance R Sewani-Rusike; Benedicta N Nkeh-Chungag Journal: Children (Basel) Date: 2020-03-28